Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 0.56 mg/ml equivalent to 0.5 mg/ml octreotide base - solution for injection - 0.5 mg/ml - active: octreotide acetate 0.56 mg/ml equivalent to 0.5 mg/ml octreotide base excipient: lactic acid mannitol sodium bicarbonate water for injection

Kanada - angielski - Health Canada

pharmascience inc - ursodiol - tablet - 250mg - ursodiol 250mg - cholelitholytic agents

Malezja - angielski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - octreotide -

Malezja - angielski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - octreotide -

Malezja - angielski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - octreotide -

Malezja - angielski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - octreotide -

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

nexgen pharma, inc. - chenodiol (unii: 0gei24lg0j) (chenodiol - unii:0gei24lg0j) - chenodiol 250 mg - chenodiol is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. the likelihood of successful dissolution is far greater if the stones are floatable or small. for patients with nonfloatable stones, dissolution is less likely and added weight should be given to the risk that more emergent surgery might result from a delay due to unsuccessful treatment. safety of use beyond 24 months is not established. chenodiol will not dissolve calcified (radiopaque) or radiolucent bile pigment stones. chenodiol is contraindicated in the presence of known hepatocyte dysfunction or bile ductal abnormalities such as intrahepatic cholestasis, primary biliary cirrhosis or sclerosing cholangitis (see warnings ); a gallbladder confirmed as non-visualizing after two consecutive single doses of dye; radiopaque stones; or gallstone complications or compelling reasons for gallblad

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

lgm pharma solutions, llc - chenodiol (unii: 0gei24lg0j) (chenodiol - unii:0gei24lg0j) - chenodiol is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. the likelihood of successful dissolution is far greater if the stones are floatable or small. for patients with nonfloatable stones, dissolution is less likely and added weight should be given to the risk that more emergent surgery might result from a delay due to unsuccessful treatment. safety of use beyond 24 months is not established. chenodiol will not dissolve calcified (radiopaque) or radiolucent bile pigment stones. chenodiol is contraindicated in the presence of known hepatocyte dysfunction or bile ductal abnormalities such as intrahepatic cholestasis, primary biliary cirrhosis or sclerosing cholangitis (see warnings ); a gallbladder confirmed as nonvisualizing after two consecutive single doses of dye; radiopaque stones; or gallstone complications or compelling reasons for gallbladd